デフォルト表紙
市場調査レポート
商品コード
707340

世界の埋め込み型ドラッグデリバリーデバイス市場 - 製品タイプ、技術、用途、地域別 - 成長率、市場動向、市場予測

Implantable Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 110 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
世界の埋め込み型ドラッグデリバリーデバイス市場 - 製品タイプ、技術、用途、地域別 - 成長率、市場動向、市場予測
出版日: 2022年01月17日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 110 Pages
納期: 2~3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の埋め込み型ドラッグデリバリーデバイス市場は、2018年から2023年にかけて、7.8%のCAGRで推移することが予測されています。ゲノミクス、プロテオミクス、バイオテクノロジー分野の技術発展と新薬の登場によって、埋め込み型ドラッグデリバリーデバイス市場の成長が促進されています。

当レポートでは、世界の埋め込み型ドラッグデリバリーデバイス市場を調査し、市場の概要、製品タイプ・技術・用途・地域別の市場規模の推移と予測、市場動向、市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 埋め込み型ドラッグデリバリーデバイス市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場力学

  • 成長要因
    • 低侵襲手術のニーズの高まり
    • 新製品の登場
    • 慢性疾患の有病率の上昇
  • 阻害要因
    • デバイスのコストの高さ
    • 厳格な規制シナリオ
  • 市場機会
  • 主な課題

第7章 埋め込み型ドラッグデリバリーデバイス市場:セグメント別

  • 製品タイプ別
    • 薬物注入ポンプ
    • 眼内ドラッグデリバリーデバイス
    • 避妊ドラッグデリバリーデバイス
    • ステント
  • 技術別
    • 生分解性インプラント
    • 非生分解性インプラント
  • 用途別
    • 腫瘍学
    • 心血管
    • 自己免疫疾患
    • 産婦人科
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 企業プロファイルと競合情勢

  • Abbott
  • Allergan
  • Boston Scientific Corporation
  • Bausch and Lomb Inc.
  • Delpor Inc.
  • Medtronic
  • Novartis
  • pSivida Corp.
  • Teleflex Incorporated
  • 3M's Health Care

第9章 市場の将来展望

目次
Product Code: 62809

The implantable drug delivery devices market is expected to witness robust growth due to the increasing geriatric population, rise in the number of cancer cases, a growing number of cardiology, ophthalmology abnormalities and the rise in technological advancements. Furthermore with the increase in the burden of chronic diseases the large patient population increases the number of surgeries and hence drives the implantable drug delivery devices market. In addition, the growing preference for drug-device combination products owing to higher efficacy also serves as a key contributing factor.

However, the high cost of devices and surgery costs, low rate of adoption are the few restraining factors of the growth of implantable drug delivery devices market.

Key Market Trends

Drug Infusion Pumps Segment is Expected to Hold a Significant Market Share

Infusion pumps are devices that are used to deliver fluids into a patient's body, in a controlled manner. They are capable of supplying medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers. Infusion pumps play an important role in delivering accurate medications in chemotherapy, for diabetics, etc., for the corresponding diseases.

The rising number of diabetes cases and increasing investments in diabetes care and management have helped in the adoption of insulin infusion pumps. Technological advancements, coupled with increasing R&D initiatives on gastrointestinal disorders, cancer, neurological problems, and AIDS, are providing lucrative opportunities for infusion pumps in the market. According to the FDA, in 2017, Baxter's Sigma Spectrum Infusion pump has been the number one infusion pump in drug library compliance. Sigma Spectrum has a user interface that provides top-quality patient safety margins and has the ability to integrate with leading electronic medical record systems.

North America Dominates the Implantable Drug Delivery Devices Market

In North America, the medical device industry is a highly regulated sector of the economy. There are several studies that suggest that the US manufacturers of implantable devices can maintain high prices, in part due to structural barriers such as costly regulatory approval processes and patent protections. Therefore, manufacturers face problems in launching new products in the United States.

Hospitals are the primary purchasers of most high-cost implantable devices in the United States, but they have limited bargaining power to negotiate for lower prices. There are millions of Americans being implanted with implantable devices such as artificial hips or cardiac pacemakers, in their bodies. Experts have also estimated that 7.2 million Americans are living with joint implants. However, due to the aging population and the increasing prevalence of chronic conditions, the number of patients adopting implantable devices continues to grow exponentially. During the past year, in the United States, there have been many advancements in technology and medical innovation, which have expanded the types of implantable devices, to include artificial hearts and deep-brain stimulators to control epilepsy.

Competitive Landscape

The market players are found focusing on new product launches, minimizing the price of the tests in order to gain maximum traction in the global market. Furthermore, market players are concentrating on various growth strategies such as collaborations, acquisitions, partnerships to enhance their market presence. In addition, market leaders are highly focused on delivering economic value and cater to unmet needs.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Minimally Invasive Procedures
    • 4.2.2 Emergence of Novel Products
    • 4.2.3 Increasing Prevalence of Chronic Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Devices
    • 4.3.2 Stringent Regulatory Requirements
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Drug Infusion Pumps
    • 5.1.2 Intraocular Drug Delivery Devices
    • 5.1.3 Contraceptive Drug Delivery Devices
    • 5.1.4 Stents
    • 5.1.5 Others
  • 5.2 By Technology
    • 5.2.1 Biodegradable Implants
    • 5.2.2 Non-biodegradable Implants
  • 5.3 By Application
    • 5.3.1 Oncology
    • 5.3.2 Cardiovascular
    • 5.3.3 Autoimmune Diseases
    • 5.3.4 Obstetrics and Gynecology
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Bausch and Lomb Inc.
    • 6.1.4 Medtronic PLC
    • 6.1.5 Alcon Inc.
    • 6.1.6 Teleflex Incorporated
    • 6.1.7 DSM Biomedical
    • 6.1.8 Delpor Inc.
    • 6.1.9 3M Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS